RA 101495

Drug Profile

RA 101495

Alternative Names: RA101495

Latest Information Update: 20 Mar 2017

Price : $50

At a glance

  • Originator Ra Pharmaceuticals
  • Class Cyclic peptides
  • Mechanism of Action Complement C5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Paroxysmal nocturnal haemoglobinuria
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Paroxysmal nocturnal haemoglobinuria
  • Preclinical Lupus nephritis; Myasthenia gravis

Most Recent Events

  • 01 Mar 2017 Phase-II clinical trials in Paroxysmal nocturnal haemoglobinuria in United Kingdom (SC) (NCT03078582)
  • 29 Nov 2016 Ra pharmaceuticals plans a phase II trial for Myasthenia gravis
  • 29 Nov 2016 Ra Pharmaceuticals plans a phase II trial for Paroxysmal nocturnal haemoglobinuria (NCT03030183)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top